Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 32Neoplasm Metastasis 6Metastatic Castration-resistant Prostate Cancer 3Urogenital Neoplasms 1Prostate Cancer Metastatic 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms 1Neoadjuvant Therapy 1Metastatic Castration-Resistant Prostate Cancer Patients 1Metastatic Castration-Resistant Prostate Cancer 1Bulbo-Spinal Atrophy, X-Linked 1Abiraterone Acetate 1

Interventions

enzalutamide 7Abiraterone Acetate 4abiraterone 3Prednisone 3Docetaxel 3sapanisertib 1relugolix 1pembrolizumab 1onvansertib 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1apalutamide 1abemaciclib 1Prednisolone 1PF06821497 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer × Prednisolone × Genitourinary × Clear all
NCT02405858 2025-02-03

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Janssen Pharmaceutical K.K.

Phase 4 Completed
51 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡